Researchers have stopped recruiting patients for a clinical trial testing Amgen Inc.'s (AMGN) colorectal-cancer treatment Vectibix in other digestive-tract cancers because it was associated with inferior outcomes in patients. The trial, sponsored by the Royal Marsden NHS Foundation Trust in the U.K., started in 2008 and was due to run until 2013, according to a U.S. database of clinical trials. It was testing whether adding Vectibix to a reduced dose of a triple-drug chemotherapy regimen would extend survival, compared with a standard dose of the chemotherapy regimen, in people with advanced stomach and esophageal cancer.
